{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:57:02Z","timestamp":1792101422112,"version":"4.4.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273782"],"award-info":[{"award-number":["82273782"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["232102311168"],"award-info":[{"award-number":["232102311168"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bioorg.2025.109105","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:54:31Z","timestamp":1760543671000},"page":"109105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Chalcones and their derivatives as inhibitors of key ABC transporters (ABCB1, ABCG2) to overcome tumor multidrug resistance"],"prefix":"10.1016","volume":"166","author":[{"given":"Yi-Fan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Bo","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109105_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114643","article-title":"Overcoming Cancer multi-drug resistance (MDR): reasons, mechanisms, nanotherapeutic solutions, and challenges","volume":"162","author":"Duan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109105_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100645","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bioorg.2025.109105_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100743","article-title":"Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance","volume":"54","author":"Wang","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bioorg.2025.109105_bb0020","first-page":"535","article-title":"The role of eukaryotic and prokaryotic ABC transporter family in failure of chemotherapy","volume":"7","author":"El-Awady","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109105_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2024.119878","article-title":"The association of ABC proteins with multidrug resistance in cancer","volume":"1872","author":"Marques","year":"2025","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"key":"10.1016\/j.bioorg.2025.109105_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114542","article-title":"Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update","volume":"239","author":"Engle","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.11.013","article-title":"Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy","volume":"149","author":"Silva","year":"2014","journal-title":"Pharmacol Therapeut"},{"key":"10.1016\/j.bioorg.2025.109105_bb0040","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1038\/s41467-021-24651-2","article-title":"Structures of ABCG2 under turnover conditions reveal a key step in the drug transport mechanism","volume":"12","author":"Yu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109105_bb0045","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.lfs.2010.02.012","article-title":"ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy","volume":"86","author":"Ding","year":"2010","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2025.109105_bb0050","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.biopha.2018.02.038","article-title":"Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR","volume":"100","author":"Mohammad","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109105_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103537","article-title":"ATP-binding cassette efflux transporters and MDR in cancer","volume":"28","author":"Pote","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.109105_bb0060","first-page":"1","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade, drug resist","volume":"18","author":"Kathawala","year":"2015","journal-title":"Update"},{"key":"10.1016\/j.bioorg.2025.109105_bb0065","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.critrevonc.2015.05.012","article-title":"The role of ABC transporters in ovarian cancer progression and chemoresistance","volume":"96","author":"Ween","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioorg.2025.109105_bb0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-017-0591-8","article-title":"The evolving role of the Estrogen receptor mutations in endocrine therapy-resistant breast Cancer","volume":"19","author":"Jeselsohn","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bioorg.2025.109105_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314672","article-title":"DNA damage response in Cancer therapy and resistance: challenges and opportunities","volume":"23","author":"Jurkovicova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109105_bb0080","doi-asserted-by":"crossref","first-page":"59950","DOI":"10.18632\/oncotarget.19048","article-title":"The molecular mechanisms of chemoresistance in cancers","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.109105_bb0085","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.180002","article-title":"Targeting BCL-2 regulated apoptosis in cancer","volume":"8","author":"Campbell","year":"2018","journal-title":"Open Biol."},{"key":"10.1016\/j.bioorg.2025.109105_bb0090","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0959-8049(96)00051-2","article-title":"Glutathione and related enzymes in multidrug resistance","volume":"32A","author":"O\u2019Brien","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2025.109105_bb0095","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3109\/07388551.2015.1015957","article-title":"Molecular mechanisms of drug resistance and its reversal in cancer","volume":"36","author":"Kartal-Yandim","year":"2016","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.bioorg.2025.109105_bb0100","first-page":"1","article-title":"Modulating ROS to overcome multidrug resistance in cancer, drug resist","volume":"41","author":"Cui","year":"2018","journal-title":"Update"},{"key":"10.1016\/j.bioorg.2025.109105_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100754","article-title":"Therapeutic strategies to overcome taxane resistance in cancer","volume":"55","author":"Das","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bioorg.2025.109105_bb0110","first-page":"14","article-title":"Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies, drug resist","volume":"27","author":"Li","year":"2016","journal-title":"Update"},{"key":"10.1016\/j.bioorg.2025.109105_bb0115","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1038\/srep08669","article-title":"Ultrasmall glutathione-protected gold nanoclusters as next generation radiotherapy sensitizers with high tumor uptake and high renal clearance","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109105_bb0120","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.actbio.2017.11.007","article-title":"Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment","volume":"65","author":"Mart\u00ednez-Carmona","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bioorg.2025.109105_bb0125","doi-asserted-by":"crossref","first-page":"1486783","DOI":"10.3389\/fphar.2024.1486783","article-title":"MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters","volume":"15","author":"Lu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109105_bb0130","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0928-0987(00)00114-7","article-title":"Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs","volume":"11","author":"Krishna","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2025.109105_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065298","article-title":"Identification and empiric evaluation of new inhibitors of the multidrug transporter P-glycoprotein (ABCB1)","volume":"24","author":"Cheema","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109105_bb0140","first-page":"670","article-title":"Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel","volume":"8","author":"Toppmeyer","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109105_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114542","article-title":"Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update","volume":"239","author":"Engle","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0150","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1634\/theoncologist.12-8-927","article-title":"Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein)","volume":"12","author":"Marchetti","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2025.109105_bb0155","article-title":"Elevated ABCB1 expression confers acquired resistance to Aurora kinase inhibitor GSK-1070916 in Cancer cells","volume":"11","author":"Wu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109105_bb0160","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1002\/1873-3468.13972","article-title":"Looking back at multidrug resistance (MDR) research and ten mistakes to be avoided when writing about ABC transporters in MDR","volume":"594","author":"Borst","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bioorg.2025.109105_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26136119","article-title":"ABCG2 transporter: from structure to function-current insights and open questions","volume":"26","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109105_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114628","article-title":"Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development","volume":"241","author":"Moinul","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115666","article-title":"Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors","volume":"259","author":"Zhu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105326","article-title":"Synthesis and biological assessment of new pyrimidopyrimidines as inhibitors of breast cancer resistance protein (ABCG2)","volume":"116","author":"Dakhlaoui","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0185","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1021\/acs.molpharmaceut.5b00463","article-title":"Predicting activators and inhibitors of the breast Cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1) based on mechanistic considerations","volume":"12","author":"Egido","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioorg.2025.109105_bb0190","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41598-020-79892-w","article-title":"Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles","volume":"11","author":"Kita","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109105_bb0195","first-page":"3481","article-title":"Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity","volume":"9","author":"Gozzi","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bioorg.2025.109105_bb0200","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in Cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109105_bb0205","article-title":"Multidrug resistance in Cancer: understanding molecular mechanisms","volume":"12","author":"Emran","year":"2022","journal-title":"Immunoprevention and Therapeutic Approaches, Front Oncol"},{"key":"10.1016\/j.bioorg.2025.109105_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107099","article-title":"Natural products for combating multidrug resistance in cancer","volume":"202","author":"Chen","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2025.109105_bb0215","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejmech.2019.05.027","article-title":"Natural products as multidrug resistance modulators in cancer","volume":"176","author":"Kumar","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0220","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3109\/14756366.2016.1149476","article-title":"Advances in plant-based inhibitors of P-glycoprotein","volume":"31","author":"Yu","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0225","first-page":"2041","article-title":"Modulators of the human ABCC2: hope from natural sources?, future","volume":"7","author":"Baiceanu","year":"2015","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0230","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.3390\/molecules25153364","article-title":"Overcoming multidrug resistance: flavonoid and terpenoid nitrogen-containing derivatives as ABC transporter modulators","volume":"25","author":"M.F.G. B, S.P.C. D, U.F. MJ","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109105_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2023.100167","article-title":"Flavonoids as promising molecules in the cancer therapy: an insight","volume":"6","author":"Mir","year":"2024","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.bioorg.2025.109105_bb0240","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.bmc.2010.12.043","article-title":"Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP)","volume":"19","author":"Pick","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0245","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3390\/biom11060894","article-title":"Chalcone derivatives: role in anticancer therapy","volume":"11","author":"Ouyang","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2025.109105_bb0250","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1080\/17460441.2024.2436908","article-title":"Advances in chalcone-based anticancer therapy: mechanisms, preclinical advances, and future perspectives","volume":"19","author":"Chowdhary","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109105_bb0255","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1039\/D5RA01280E","article-title":"Excavating medicinal virtues of chalcones to illuminate a new scope in cancer chemotherapy","volume":"15","author":"Roy","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109105_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110297","article-title":"Chalcones: promising therapeutic agents targeting key players and signaling pathways regulating the hallmarks of cancer","volume":"369","author":"WalyEldeen","year":"2023","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2025.109105_bb0265","first-page":"22","article-title":"Significance of chalcone scaffolds in medicinal","volume":"382","author":"Mazumder","year":"2024","journal-title":"Chemistry"},{"key":"10.1016\/j.bioorg.2025.109105_bb0270","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fmicb.2012.00130","article-title":"Secondary metabolites from plants inhibiting ABC transporters and reversing resistance of Cancer cells and microbes to cytotoxic and antimicrobial agents","volume":"3","author":"Wink","year":"2012","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bioorg.2025.109105_bb0275","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1021\/np100797y","article-title":"Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2","volume":"74","author":"Versiani","year":"2011","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2025.109105_bb0280","first-page":"1456","article-title":"Exploring natural chalcones: innovative extraction techniques, bioactivities, and health potential, sustainable","volume":"2","author":"Samota","year":"2024","journal-title":"Food Technol."},{"key":"10.1016\/j.bioorg.2025.109105_bb0285","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3109\/03602531003758690","article-title":"Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer","volume":"42","author":"Li","year":"2010","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bioorg.2025.109105_bb0290","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jep.2016.04.005","article-title":"Cytotoxicity of south-African medicinal plants towards sensitive and multidrug-resistant cancer cells","volume":"186","author":"Saeed","year":"2016","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bioorg.2025.109105_bb0295","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1002\/ptr.6180","article-title":"Millepachine showed novel antitumor effects in cisplatin-resistant human ovarian cancer through inhibiting drug efflux function of <scp>ATP<\/scp>\u2212binding cassette transporters","volume":"32","author":"Wu","year":"2018","journal-title":"Phytother. Res."},{"key":"10.1016\/j.bioorg.2025.109105_bb0300","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10637-019-00781-9","article-title":"Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt\/\u03b2-catenin signal pathway","volume":"38","author":"Hou","year":"2020","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bioorg.2025.109105_bb0305","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.3390\/molecules26154637","article-title":"Isobavachalcone as an active membrane perturbing agent and inhibitor of ABCB1 multidrug transporter","volume":"26","author":"Palko-\u0141abuz","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109105_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116219","article-title":"Marein, a novel natural product for restoring chemo-sensitivity to cancer cells through competitive inhibition of ABCG2 function","volume":"228","author":"Li","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109105_bb0315","article-title":"Comparative study on the MDR reversal effects of selected chalcones","volume":"2011","author":"Ivanova","year":"2011","journal-title":"Int J Med Chem"},{"key":"10.1016\/j.bioorg.2025.109105_bb0320","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.bmc.2012.02.050","article-title":"Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors","volume":"20","author":"Gu","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0325","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.bmc.2014.02.005","article-title":"Synthesis, biological evaluation and 3D-QSAR studies of new chalcone derivatives as inhibitors of human P-glycoprotein","volume":"22","author":"Parveen","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0330","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejmech.2019.05.053","article-title":"Design, synthesis and biological evaluation of chalcones as reversers of P-glycoprotein-mediated multidrug resistance","volume":"180","author":"Yin","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0335","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.21873\/anticanres.13864","article-title":"New chalcone derivative inhibits ABCB1 in multidrug resistant T-cell lymphoma and Colon adenocarcinoma cells","volume":"39","author":"\u010ci\u017em\u00e1rikov\u00e1","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bioorg.2025.109105_bb0340","doi-asserted-by":"crossref","first-page":"16187","DOI":"10.1021\/acs.jmedchem.1c01498","article-title":"Discovery of the triazolo[1,5-a]pyrimidine-based derivative WS-898 as a highly efficacious and orally bioavailable ABCB1 inhibitor capable of overcoming multidrug resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0345","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.3390\/molecules28114537","article-title":"Design, synthesis, and anti-cervical Cancer and reversal of tumor multidrug resistance activity of novel nitrogen-containing heterocyclic chalcone derivatives","volume":"28","author":"Yang","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109105_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107498","article-title":"Design, synthesis, and ex vivo anti-drug resistant cervical cancer activity of novel molecularly targeted chalcone derivatives","volume":"149","author":"Yang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107310","article-title":"Design and synthesis of novel imidazole-chalcone derivatives as microtubule protein polymerization inhibitors to treat cervical cancer and reverse cisplatin resistance","volume":"147","author":"Liu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0360","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bmc.2011.10.074","article-title":"Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein","volume":"20","author":"Juvale","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0365","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1021\/jm2016528","article-title":"Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity","volume":"55","author":"Valdameri","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0370","first-page":"1043","article-title":"New structure-activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity","volume":"7","author":"Rangel","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bioorg.2025.109105_bb0375","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1021\/jm401879z","article-title":"Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones","volume":"57","author":"Winter","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0380","first-page":"609","article-title":"Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position","volume":"8","author":"Winter","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bioorg.2025.109105_bb0385","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejmech.2016.03.067","article-title":"The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP\/ABCG2)","volume":"117","author":"Kraege","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0390","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1021\/acsmedchemlett.8b00289","article-title":"Tariquidar-related chalcones and ketones as ABCG2 modulators","volume":"9","author":"Pe\u00f1a-Sol\u00f3rzano","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109105_bb0395","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejmech.2018.12.019","article-title":"Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2","volume":"164","author":"Silbermann","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0400","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1016\/j.bmcl.2016.09.076","article-title":"Halogenated naphthochalcones and structurally related naphthopyrazolines with antitumor activity","volume":"26","author":"Schmitt","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109105_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113848","article-title":"Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2\/ABCB1 inhibitor","volume":"175","author":"Cai","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109105_bb0410","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ejmech.2018.09.061","article-title":"Discovery of traditional Chinese medicine monomers and their synthetic intermediates, analogs or derivatives for battling P-gp-mediated multi-drug resistance","volume":"159","author":"Ma","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0415","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10311-019-00959-w","article-title":"Chalcone synthesis, properties and medicinal applications: a review","volume":"18","author":"Rammohan","year":"2020","journal-title":"Environ. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109105_bb0420","doi-asserted-by":"crossref","first-page":"7177","DOI":"10.3390\/molecules26237177","article-title":"Chalcone scaffolds, bioprecursors of flavonoids: chemistry, bioactivities, and pharmacokinetics","volume":"26","author":"Rudrapal","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109105_bb0425","first-page":"379","article-title":"MDR-reversal activity of chalcones","volume":"22","author":"Ivanova","year":"2008","journal-title":"In Vivo"},{"key":"10.1016\/j.bioorg.2025.109105_bb0430","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cbi.2018.07.005","article-title":"New chalcone derivative exhibits antiproliferative potential by inducing G2\/M cell cycle arrest, mitochondrial-mediated apoptosis and modulation of MAPK signalling pathway","volume":"292","author":"Takac","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2025.109105_bb0435","doi-asserted-by":"crossref","first-page":"15979","DOI":"10.1021\/acs.jmedchem.0c01741","article-title":"Structure-based design, synthesis, and biological evaluation of new triazolo[1,5-a]pyrimidine derivatives as highly potent and orally active ABCB1 modulators","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0440","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/jm201404w","article-title":"Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein","volume":"55","author":"Valdameri","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0445","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1016\/j.bmcl.2008.09.105","article-title":"Synthetic chalcones as efficient inhibitors of mycobacterium tuberculosis protein tyrosine phosphatase PtpA","volume":"18","author":"Chiaradia","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109105_bb0450","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1021\/jm2012062","article-title":"Synthesis, biological evaluation, and molecular modeling of chalcone derivatives as potent inhibitors of mycobacterium tuberculosis protein tyrosine phosphatases (PtpA and PtpB)","volume":"55","author":"Chiaradia","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0455","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4155\/bio-2020-0267","article-title":"Flow cytometry: principles, applications and recent advances","volume":"13","author":"Manohar","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.bioorg.2025.109105_bb0460","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312827","article-title":"The MTT assay: utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis","volume":"22","author":"Ghasemi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109105_bb0465","doi-asserted-by":"crossref","DOI":"10.15252\/msb.202211017","article-title":"Computational estimation of quality and clinical relevance of cancer cell lines","volume":"18","author":"Trastulla","year":"2022","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.bioorg.2025.109105_bb0470","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1038\/sj.onc.1206950","article-title":"Transcriptional regulation of ABC drug transporters","volume":"22","author":"Scotto","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.109105_bb0475","doi-asserted-by":"crossref","first-page":"253","DOI":"10.20892\/j.issn.2095-3941.2019.0284","article-title":"ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance","volume":"17","author":"Muriithi","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bioorg.2025.109105_bb0480","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1021\/acs.jmedchem.5b01684","article-title":"Role of molecular dynamics and related methods in drug discovery","volume":"59","author":"De Vivo","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0485","article-title":"An updated review on developing small molecule kinase inhibitors using computer-aided drug design approaches","volume":"24","author":"Li","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109105_bb0490","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-018-0680-3","article-title":"Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states","volume":"563","author":"Manolaridis","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109105_bb0495","doi-asserted-by":"crossref","first-page":"26245","DOI":"10.1073\/pnas.2010264117","article-title":"Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1","volume":"117","author":"Nosol","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2025.109105_bb0500","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00280-015-2845-1","article-title":"Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors","volume":"76","author":"Fox","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109105_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114346","article-title":"Targeting breast cancer resistance protein (BCRP\/ABCG2): functional inhibitors and expression modulators","volume":"237","author":"Zattoni","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25189973","article-title":"Progress in research of nanotherapeutics for overcoming multidrug resistance in Cancer","volume":"25","author":"Maimaitijiang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109105_bb0515","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29173994","article-title":"Overcoming Cancer drug resistance with nanoparticle strategies for key protein inhibition","volume":"29","author":"Yoo","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109105_bb0520","first-page":"2548","article-title":"Mechanistic insights into P-glycoprotein ligand transport and inhibition revealed by enhanced molecular dynamics simulations, Comput struct","volume":"23","author":"Elbahnsi","year":"2024","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.bioorg.2025.109105_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101009","article-title":"Second-site suppressor mutations reveal connection between the drug-binding pocket and nucleotide-binding domain 1 of human P-glycoprotein (ABCB1)","volume":"71","author":"Murakami","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bioorg.2025.109105_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108709","article-title":"A comprehensive review on the role of nitrogen containing heterocycles in overcoming ABC transporter mediated multidrug resistance in cancer","volume":"163","author":"Naik","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109105_bb0535","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","article-title":"Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters","volume":"23","author":"Sajid","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.109105_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106997","article-title":"Recent developments of P-glycoprotein inhibitors and its structure\u2013activity relationship (SAR) studies","volume":"143","author":"Zhao","year":"2024","journal-title":"Bioorg. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682500985X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682500985X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T11:39:11Z","timestamp":1766057951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682500985X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":108,"alternative-id":["S004520682500985X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109105","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chalcones and their derivatives as inhibitors of key ABC transporters (ABCB1, ABCG2) to overcome tumor multidrug resistance","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109105"}}